Vulvar Melanoma with Vaginal Extension

11th Mar, 2026

Hematology/Oncology

The New England Journal of Medicine

A 49-year-old woman presented with a 6-month history of an itchy lump on her vulva. Examination showed a painless purple mass originating in the labia minora on the left side.

Published By: The New England Journal of Medicine

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Heads or the Tail?

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Gene Therapy for Nephropathic Cystinosis

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Vulvar Melanoma with Vaginal Extension

Related Articles

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Heads or the Tail?

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Gene Therapy for Nephropathic Cystinosis

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Vulvar Melanoma with Vaginal Extension

Related Articles

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Heads or the Tail?

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Gene Therapy for Nephropathic Cystinosis

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors